Señales en vivo de FRLN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 feb 2024 @ 15:37):

Stats
Volumen de hoy	5 349.00
Volumen promedio	28 144.00
Capitalización de mercado	28.28M
EPS	$0 ( 2024-04-02 )
Próxima fecha de ganancias	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.569
ATR14	$0.0640 (0.99%)

Volumen Correlación

Largo: -0.38 (neutral)

Corto: 0.00 (neutral)

Signal:(61.011) Neutral

Freeline Therapeutics Correlación

10 Correlaciones Más Positivas
INVZ	0.906
VEEE	0.895
PSTV	0.891
ISUN	0.891
COMM	0.889
MTCH	0.887
DIBS	0.886
BBIG	0.884
ICCC	0.879
NEGG	0.877

10 Correlaciones Más Negativas
TYHT	-0.846
RAM	-0.825
SVFC	-0.82
CPTA	-0.816
ALDX	-0.807
SCR	-0.804
VERX	-0.803
EBSB	-0.803
AAON	-0.802
BLCT	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Freeline Therapeutics Correlación - Moneda/Commodity

0.60
( weak )

0.55
( weak )

-0.56
( weak negative )

0.63
( weak )

0.17
( neutral )

-0.28
( neutral )

Freeline Therapeutics Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.93

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-6.81

Financial Reports:

No articles found.

Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.